Hormetic response of resveratrol against cardioprotection.
Resveratrol, a grape- and red wine-derived polyphenolic phytoalexin, shows diverse health benefits including cardioprotection. Recent studies implicate that resveratrol displays hormetic action, protecting the cells at a lower dose while killing them at relatively higher doses. Because such hormetic behaviour may have a significant impact on epidemiological and clinical studies, the present study sought to determine dose-response curves for resveratrol action. In parallel, another resveratrol formulation was tested, namely, Longevinex (Resveratrol Partners LLC, USA). A group of rats were force-fed three different doses of resveratrol or Longevinex (2.5 mg/kg, 25 mg/kg and 100 mg/kg) for up to 30 days, while the control group was only given placebo. The results showed hormesis for pure resveratrol, which was cardioprotective at lower doses and detrimental for higher doses, but surprisingly Longevinex did not display any hormetic action. In the concentration range studied, Longevinex remained cardioprotective even at 100 mg/100 g body weight - a dose that killed 100% of the hearts when tested with pure resveratrol. To further test whether Longevinex doses are beneficial for other animal species, Longevinex was gavaged to a group of rabbits for six months, and showed exactly the same degree of cardioprotection. Cardioprotection was examined in isolated working hearts subjected to 30 min of ischemia followed by 2 h of reperfusion; left ventricular performance and infarct size was also examined. It appears that Longevinex does not show any hormetic action, while resveratrol clearly does.
Cardiovascular Research Center, University of Connecticut School of Medicine, Connecticut, USA;
Bela
B
Juhasz
Subhendu
S
Mukherjee
Dipak K
DK
Das
J Cardiovasc Pharmacol. 2009 Dec;54(6):468-76
19770673
Recent Pat Cardiovasc Drug Discov. 2007 Jun;2(2):133-8
18221111
Annu Rev Public Health. 2001;22:15-33
11274508
Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2101-9
17034353
Free Radic Biol Med. 1999 Jul;27(1-2):160-9
10443932
Circulation. 2002 Sep 24;106(13):1652-8
12270858
Ageing Res Rev. 2008 Jan;7(1):63-78
17964227
Mol Interv. 2006 Feb;6(1):36-47
16507749
Nature. 2004 Aug 5;430(7000):686-9
15254550
Lancet. 1992 Jun 20;339(8808):1523-6
1351198
Heart Fail Rev. 2010 Sep;15(5):467-77
20238161
Free Radic Res. 2006 Oct;40(10):1066-75
17015251
J Nutr Biochem. 2009 Jun;20(6):443-52
18789672
Arch Biochem Biophys. 2003 Dec 15;420(2):305-11
14654070
Free Radic Biol Med. 2009 Mar 1;46(5):573-8
19071213
Clin Cardiol. 1997 May;20(5):420-4
9134271